Meropenem Acs Dobfar

Meropenem, the active ingredient in Meropenem Acs Dobfar, is a carbapenem antibiotic presented as an injectable powder for intravenous use. It treats a range of serious bacterial infections in hospitalized patients, including intra‑abdominal infections, pneumonia, and meningitis. GNH USA supplies Meropenem Acs Dobfar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for severe bacterial infections that require intravenous therapy. - Complicated intra‑abdominal infections: provides bactericidal activity against mixed flora in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: eradicates resistant Gram‑negative pathogens in complicated UTIs. - Hospital‑acquired pneumonia: effective against multidrug‑resistant organisms causing nosocomial pneumonia. - Ventilator‑associated pneumonia: treats ventilator‑related lung infections with high bacterial load. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis. - Severe sepsis and septic shock: offers rapid bacterial clearance in critically ill patients.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Infusion site phlebitis: pain or redness at the injection site. - Elevated liver enzymes: transient increase in ALT/AST. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction. - Severe neutropenia: marked reduction in neutrophil count. - Renal toxicity: acute kidney injury in susceptible individuals. - Severe allergic reactions: including Stevens‑Johnson syndrome.

Use meropenem with caution and observe clinical guidelines for high‑risk patients. - Renal function: assess creatinine clearance and adjust dose in renal impairment. - Allergy: avoid in patients with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: monitor neurologic status in patients with CNS disorders or high doses. - Superinfection: watch for fungal overgrowth or C. difficile colitis during prolonged therapy. - Pregnancy: safety not established; prescribe only when benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other drugs, requiring vigilance.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate levels, risking seizure breakthrough. - Concurrent nephrotoxic agents (e.g., aminoglycosides): may exacerbate renal injury. - Other carbapenems: combined use increases risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: monitor renal function when used together. - Warfarin: observe INR for potential anticoagulation changes. - Oral contraceptives: efficacy may be reduced; advise alternative contraception.